UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(dD) of ~~the~~The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~December 926, ~~2022~~2024

Yubo International Biotech Limited (Exact name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

New York	0000-21320	11-3074326
(State or Other Jurisdictionof Incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdictionof incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)

Room 105, Building 5, 31 Xishiku AvenueXicheng District, Beijing, China		100032
Room 105, Building 5, 31 Xishiku Avenue, Xicheng District, Beijing, China		100034
(Address of Principal Executive Offices)		(Zip Code)
(Address of principal executive offices)		(Zip Code)

Registrant’s ~~Telephone~~telephone ~~Number~~number, ~~Including~~including ~~Area~~area ~~Code~~code: +86 (~~010~~040) ~~6615~~0677-~~5141~~6010

Not Applicable

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since ~~Last~~last ~~Report~~report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instructions A.2. below)~~:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Not Applicable

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 74.01 ~~Regulation~~Changes FDin ~~Disclosure~~Registrant’s Certifying Accountant.

~~On November 9, 2022, Focus Draw Group Limited and DragonCloud Technology Limited~~ (collectively, the “Selling Stockholders”) completed the sales of an aggregate amount of 4,728,000 shares and 5,768,100 shares, respectively, of Class A Common Stock, par value $0.001 per share (“Common Stock”), of Yubo International Biotech Limited, a ~~New York corporation (the “Company”~~), asDismissal ~~selling stockholders in a registered offering~~ of ~~the~~Independent ~~Company~~Registered ~~(the~~Public ~~“Offering”).~~Accounting The shares of Common Stock were sold by the Selling Stockholders at $0.50 per share to certain non-affiliates of the Company, pursuant to the Stock Purchase Agreements, dated as of September 23, 2022, each entered into by and among the applicable Selling Stockholder, the Company, and the applicable non-affiliate purchaser. The Company did not receive any of the proceeds from the sales of Common Stock sold by the Selling Stockholders in the Offering.Firm

~~The~~On ~~Offering~~December ~~was~~26, ~~registered~~2024, ~~pursuant~~Yubo toInternational aBiotech ~~registration~~Limited, ~~statement~~a onNew ~~Form~~York ~~S-1~~corporation (~~File~~the ~~No. 333-255805~~“Company”), ~~including~~dismissed ~~all~~Michael ~~amendments~~T. ~~thereto,~~Studer ~~the~~CPA ~~exhibits~~P.C. ~~and~~(“MTS ~~any~~CPA”) ~~schedules~~as ~~thereto,~~ the ~~documents,~~Company’s ~~otherwise~~independent ~~deemed~~registered topublic beaccounting ~~part~~firm ~~thereof~~in orlight ~~included~~of ~~therein (~~the ~~“Registration~~retirement ~~Statement”)~~of ~~filed~~Mr. ~~with~~Studer, the Upresident of MTS CPA.S. ~~Securities~~The ~~and~~dismissal ~~Exchange~~was ~~Commission~~approved by the board of directors (the “~~SEC~~Board”), ~~which~~of ~~was~~the ~~declared~~Company ~~effective~~and bybecame ~~the~~effective ~~SEC~~ on ~~July~~January 292, ~~2022~~2025.

~~Item~~MTS ~~8.01~~CPA’s ~~Other~~report ~~Events~~on the financial statements of the Company for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, nor was such report qualified or modified as to uncertainty, audit scope, or accounting principle, other than an explanatory paragraph regarding the Company’s ability to continue as a going concern.

~~The~~During ~~information~~the inCompany’s ~~Item~~fiscal ~~7.01~~years ~~above~~ended isDecember ~~incorporated~~31, ~~herein~~2023 byand December 31, 2022 and the subsequent interim period from January 1, 2024 to December 26, 2024, (i) there were no disagreements with MTS CPA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of MTS CPA, would have caused MTS CPA to make reference to the subject matter of the disagreements in ~~this~~connection with its report, and (ii) there were no “reportable events” as such term is defined in Item 8304(a)(1)(v) of Regulation S-K.~~01.~~

The ~~information~~Company ~~contained~~has inrequested ~~Item~~that ~~7.01~~MTS ~~above~~CPA ~~and~~furnish ~~this~~to ~~Item 8.01 and~~ the ~~exhibits~~Company ~~hereto~~a ~~shall~~letter ~~not~~addressed ~~be deemed~~ to ~~be “filed” for purposes of Section 18 of~~ the U.S. Securities ~~Exchange~~and ~~Act of 1934, as amended (the “~~Exchange ~~Act”),~~Commission ~~and~~stating ~~shall~~whether or not beMTS ~~incorporated~~CPA byagrees ~~reference~~with ~~into any filings made by~~ the ~~Company~~above ~~under~~statements. ~~the~~A ~~Securities~~copy ~~Act~~ of ~~1933,~~such ~~as amended~~letter, ordated ~~the~~January ~~Exchange~~6, ~~Act~~2025, ~~except~~is filed as ~~may~~Exhibit be16.1 ~~expressly~~to ~~set~~this ~~forth~~current byreport ~~specific~~on ~~reference~~Form ~~in such filing~~8-K.

~~Item~~(b) ~~9.01~~Engagement ~~Financial~~of ~~Statements~~New ~~and~~Independent ~~Exhibits.~~Registered Public Accounting Firm

On December 26, 2024, the Company engaged HHL Advisors Group (d“HHL”) ~~Exhibits~~ as its new independent registered public accountant, effective January 2, 2025. The engagement was approved by the Board.

Exhibit No.		Description
99.1*		Stock Purchase Agreement, dated September 23, 2022, by and among Focus Draw Group Limited, Yubo International Biotech Limited and World Precision Medicine Technology Limited
99.2*		Stock Purchase Agreement, dated September 23, 2022, by and among Focus Draw Group Limited, Yubo International Biotech Limited and Xu Xiuqun
99.3*		Stock Purchase Agreement, dated September 23, 2022, by and among DragonCloud Technology Limited, Yubo International Biotech Limited and Xu Xiuqun
99.4*		Stock Purchase Agreement, dated September 23, 2022, by and among DragonCloud Technology Limited, Yubo International Biotech Limited and Sun Weitao
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

During the Company’s fiscal years ended December 31, 2023 and December 31, 2022 and the subsequent interim period from January 1, 2024 to December 26, 2024, neither the Company nor anyone on its behalf consulted with HHL regarding (i) the application of accounting principles to a specified transaction, completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that HHL concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or any “reportable event” as such term is defined in Item 304(a)(1)(v) of Regulation S-K.

*Item ~~Certain~~9.01. ~~portions~~Financial ofStatements ~~this~~and ~~exhibit have been redacted to remove personally identifiable information~~Exhibits.

2(d) Exhibits

SIGNATURE

Exhibit No.		Description
16.1		Letter from Michael T. Studer CPA P.C.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

	Yubo International Biotech Limited
Dated: November 10, 2022	By:	/s/ Lina Liu
		Name: Lina Liu
		Title: Chief Financial Officer

SIGNATURE

3Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 6, 2025	Yubo International Biotech Limited

	By:	/s/ Lina Liu
		Name: Lina Liu
		Title: Chief Financial Officer

Filing Compare · Yubo International Biotech Ltd